PBA
IMTX icon

Paradigm Biocapital Advisors’s Immatics IMTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio IMTX Stock Details IMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,144,157
Closed -$16.9M – 38
2025
Q2 		$16.9M Buy
3,144,157
+1,237,049
+65% +$6.14M 0.72% 26
2025
Q1 		$8.6M Sell
1,907,108
-3,507,301
-65% -$18.3M 0.39% 28
2024
Q4 		$38.5M Buy
5,414,409
+1,509,547
+39% +$13M 1.34% 18
2024
Q3 		$44.6M Buy
3,904,862
+482,897
+14% +$5.72M 1.51% 22
2024
Q2 		$39.8M Buy
3,421,965
+603,057
+21% +$6.8M 1.52% 21
2024
Q1 		$29.6M Buy
2,818,908
+682,569
+32% +$7.96M 1.04% 24
2023
Q4 		$22.5M Buy
2,136,339
+77,892
+4% +$717K 1.05% 21
2023
Q3 		$23.8M Buy
2,058,447
+73,634
+4% +$879K 1.62% 22
2023
Q2 		$22.9M Buy
+1,984,813
New +$18.5M 1.77% 23

Other funds holding IMTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Paradigm Biocapital Advisors's IMTX Position: Q3 2025 in Review

Paradigm Biocapital Advisors sold out of Immatics (IMTX) in Q3 2025, closing a stake of 3,144,157 shares — an estimated $16.9M sold.

Paradigm Biocapital Advisors first reported a position in IMTX in Q2 2023 and held it in 9 quarters. The position peaked at $44.6M in Q3 2024. 63 funds tracked by Wall St. Rank hold IMTX as of Q3 2025.

  • Paradigm Biocapital Advisors reported no remaining Immatics position as of Q3 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 3,144,157 Immatics shares in Q3 2025, an estimated $16.9M.
  • Paradigm Biocapital Advisors first reported a position in Immatics in Q2 2023 and held it in 9 quarters.
  • Paradigm Biocapital Advisors's Immatics position peaked at $44.6M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Immatics as of Q3 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.